

# **Water-Insoluble Drug Formulation**



**Edited by  
Rong Liu**



**Interpharm/CRC**

### Library of Congress Cataloging-in-Publication Data

Water-insoluble drug formulation / Rong Liu, editor.

p. cm.

Includes bibliographical references and index.

ISBN 1-57491-105-8

1. Solutions (Pharmacy) 2. Drugs—Solubility. I. Liu, Jung.

RS201.S6W38 2000

615'42—dc21

00-033450

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the authors and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.

The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying.

Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.

**Visit the CRC Press Web site at [www.crcpress.com](http://www.crcpress.com)**

© 2000 by CRC Press LLC

Interpharm is an imprint of CRC Press LLC

No claim to original U.S. Government works

International Standard Book Number 1-57491-105-8

Library of Congress Card Number 00-033450

Printed in the United States of America 1 2 3 4 5 6 7 8 9 0

Printed on acid-free paper

Preformulation Studies	501
Formulation Development	502
Methods of Manufacture	507
Processing Issues	511
Product Testing and Specifications	513
Applications	515
Future Perspective	516
References	517
 <b>15. Alteration of the Solid State of the Drug Substance: Polymorphs, Solvates, and Amorphous Forms</b>	 <b>525</b>
<i>Michael J. Jozwiakowski</i>	
Theoretical and Practical Considerations	526
Special Considerations for Polymorphs	546
Solvates and Hydrates of Drugs	549
The Utility of Amorphous (Noncrystalline) Forms	555
Strategy for Water-Insoluble Drug Formulation Using Metastable Solids	561
References	562
 <b>16. Solubilization Systems—The Impact of Percolation Theory and Fractal Geometry</b>	 <b>569</b>
<i>Hans Leuenberger Silvia Kocova El-Arini</i>	
Introduction to Percolation Theory	570
References	589
Experiences with a Novel Fluidized Bed System Operating under Vacuum Conditions	591
Applications	596
An Alternative Novel Process Technology to Obtain Well-soluble Substances: Atmospheric Spray-freeze Drying	597

## Alteration of the Solid State of the Drug Substance: Polymorphs, Solvates, and Amorphous Forms

---

Michael J. Jozwiakowski  
*3M Pharmaceuticals*  
*St. Paul, Minnesota*

The maximum solubility of a drug substance is a function of the nature of the solid phase in equilibrium with a specified solvent system at a given temperature and pressure. Solubility is an equilibrium constant for the dissolution of the solid into the solvent and thus depends on the competition of solute:solvent interactions and solid:solid interactions. Alteration of the solid phase of the drug substance can influence its solubility and dissolution properties by affecting the molecular interactions in the solid.

A crystal of higher free energy will yield an apparent higher solubility than a lower energy stable crystal form of the same molecular structure. In the lowest energy solid state, the energetically favorable solid:solid interactions reduce the escaping tendency of the molecules, and thus fewer molecules dissolve in a given solvent under the same set of environmental conditions. Crystalline polymorphs, solvates and hydrates, and amorphous forms of drug substances have been used to change the thermodynamic driving force for dissolution and to increase the apparent solubility of poorly soluble drugs.

Unlike solubilization techniques that change the nature of the solvent environment (cosolvent systems, emulsions, micellization) or the chemical identity of the dissolved solute (salt formation, complexation, pro-drugs), manipulation of the solid state of the drug substance results in only a transient change in the system. Since the solvent

and the chemical form are identical, the system will ultimately revert to the lowest-energy solid phase in equilibrium with the solvent, with the lowest solubility. Crystal growth and dissolution have been used to assign relative physical stability for polymorphs by observing the direction of the transformation under a microscope under controlled temperature in contact with a solvent. The rate of transformation in contact with a solvent is normally too fast to consider solution or suspension dosage forms of metastable solids. Systems with unusually large energy barriers, slow reversion kinetics, or excipients to retard crystallization can be useful in limited circumstances.

The most practical use of this technique is to alter the solid phase in dry dosage forms where molecular mobility is greatly reduced. Metastable forms of solid drugs are often stable to physical transformation in the time context required for marketable formulations. Tablets, capsules, lyophilized powders, granules for constitution, and other solid dosage forms are ideal systems for incorporation of metastable solid phases. In most cases, the brief exposure to gastrointestinal (GI) fluids does not result in conversion to the lower solubility form prior to generating the desired enhanced effect. Solid-state transformations and transformations induced by adsorbed water during long-term storage can still be problematic. Any consideration of formulating metastable solid phases must balance the expected gain in efficacy with the potential for reversion to the less-favorable form prior to patient use. This involves both an understanding of the phase diagrams (which forms are physically stable under which conditions) and the physical principles governing transformation kinetics.

In this chapter, the theoretical and practical considerations for the use of metastable solids in formulations to gain a solubility or dissolution-rate advantage are explored. Experiments are suggested that identify the potential solid forms of the drug and elucidate the potential advantages and disadvantages. Specific examples of the degree of enhancement that can be expected and special considerations for each type of solid are covered (polymorphs, solvates, and amorphous forms).

## THEORETICAL AND PRACTICAL CONSIDERATIONS

### Importance of the Solid State of the Drug

#### *Origin of the Effect of Solid State on Solubility*

When a medicinal chemist discovers a new chemical entity (NCE) with a desired pharmacological effect, structure-activity relationships are used to optimize the series for activity. Aqueous solubility, partition coefficient, crystallinity, melting point, particle size, and hygroscopicity, all of interest to the formulator of this NCE, will also vary within the series of drug candidates. Because the biological activity is often estimated by target enzyme binding studies in very dilute media, solubility may not be optimized simultaneously. If an ionizable drug candidate is selected, the choice of free acid/base form versus the salt forms again produces a myriad of possible physical properties. The alteration of solubility by judicious choice of the salt was covered in a

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.